The management of Guillain–Barré syndrome

Abstract 

Guillain–Barré syndrome (GBS) is a rare cause of severe polyneuropathy in children. We now recognise that GBS is made up of distinct subtypes, with different clinical, electrodiagnostic and pathological findings. The diagnosis of GBS is based on the classical triad of weakness, areflexia and elevated cerebrospinal fluid (CSF) protein without pleocytosis. Early recognition and effective treatment of GBS may reduce morbidity and mortality.

The management of GBS includes acute treatment of the paralysis and associated complications, the treatment of the underlying cause, and the long-term rehabilitation of the patient.

This article aims to provide a clear evidence-linked care pathway for the management of GBS from the time of presentation to rehabilitation.

Keywords:  Children, Guillain–Barré syndrome, Management, Immunotherapy, Demyelination, Neuropathy